Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RECURSION PHARMACEUTICALS, INC.

(RXRX)
  Report
Delayed Nasdaq  -  04:00 2022-09-29 pm EDT
10.74 USD   -7.89%
09/23Beyond The Deal : Recursion's Transformational Partnership with Roche and Genentech
PU
09/19Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) added to S&P Biotechnology Select Industry Index
CI
09/16KeyBanc Starts Recursion Pharmaceuticals at Overweight With $20 Price Target
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/23/2022 09/26/2022 09/27/2022 09/28/2022 09/29/2022 Date
10.79(c) 9.97(c) 10.89(c) 11.66(c) 10.74 Last
1 050 364 950 710 1 192 300 1 173 244 1 135 441 Volume
+0.75% -7.60% +9.23% +7.07% -7.89% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 45,5 M - -
Net income 2022 -221 M - -
Net cash position 2022 252 M - -
P/E ratio 2022 -7,85x
Yield 2022 -
Sales 2023 58,4 M - -
Net income 2023 -243 M - -
Net cash position 2023 152 M - -
P/E ratio 2023 -7,43x
Yield 2023 -
Capitalization 2 018 M 2 018 M -
EV / Sales 2022 38,8x
EV / Sales 2023 31,9x
Nbr of Employees 400
Free-Float 84,1%
More Financials
Company
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company decoding biology by integrating technology across biology, chemistry, automation, machine learning, and engineering to industrialize drug discovery. The Company’s platform includes the Recursion Operating System, which combines an advanced infrastructure layer to generate proprietary biological and chemical datasets, and the Recursion Map, a... 
More about the company
Ratings of Recursion Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about RECURSION PHARMACEUTICALS, INC.
09/23Beyond The Deal : Recursion's Transformational Partnership with Roche and Genentech
PU
09/19Recursion Pharmaceuticals, Inc.(NasdaqGS:RXRX) adde..
CI
09/16KeyBanc Starts Recursion Pharmaceuticals at Overweight With $20 Price Target
MT
09/13Recursion Pharmaceuticals Starts Two New Clinical Trials of REC-4481, REC-3964
MT
09/13Recursion Pharmaceuticals, Inc. : Other Events, Financial Statements and Exhibits (form 8-..
AQ
09/13Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022
PR
09/13Recursion Initiates Two Additional Clinical Trials for A Total of Four in 2022
CI
09/01Recursion to Participate in Upcoming Investor Conferences
PR
08/18Insider Sell: Recursion Pharmaceuticals
MT
08/18Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs G..
PR
08/11Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $8 From $7, Keeps Neut..
MT
08/09Recursion Pharmaceuticals : Q2 Earnings Snapshot
AQ
08/09Recursion Pharmaceuticals : Provides Business Updates and Reports Second Quarter 2022 Fina..
PU
08/09RECURSION PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Cond..
AQ
08/09Recursion Pharmaceuticals, Inc. : Results of Operations and Financial Condition, Regulatio..
AQ
More news
News in other languages on RECURSION PHARMACEUTICALS, INC.
09/13Recursion Pharmaceuticals lance deux nouveaux essais cliniques sur les produits REC-448..
09/13Recursion lance deux essais cliniques supplémentaires pour un total de quatre en 2022
08/18Vente d'initiés : Recursion Pharmaceuticals
08/09Earnings Flash (RXRX) RECURSION annonce un chiffre d'affaires de 7,7 millions de dollar..
08/09Recursion Pharmaceuticals, Inc. annonce ses résultats pour le deuxième trimestre et le ..
More news
Analyst Recommendations on RECURSION PHARMACEUTICALS, INC.
More recommendations
ETFs positioned on RECURSION PHARMACEUTICALS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
ALPS Medical Breakthroughs ETF - USD0.85%2.09%United_States
Virtus LifeSci Biotech Clinical Trials ETF - USD0.82%3.63%United_States
HAN-GINS Indxx Healthcare Megatrend Equal W...0.8%-3.85%-NC
First Trust Small Cap Growth AlphaDEX Fund - USD0.24%-2.55%NC
IShares Nasdaq US Biotechnology - USD0.14%-0.99%United_States
More ETFs positioned on RECURSION PHARMACEUTICALS, INC.
Chart RECURSION PHARMACEUTICALS, INC.
Duration : Period :
Recursion Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECURSION PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 11,66 $
Average target price 17,00 $
Spread / Average Target 45,8%
EPS Revisions
Managers and Directors
Chistopher C. Gibson Chief Executive Officer & Director
Tina Larson Chief Operating Officer
Michael Secora Chief Financial Officer
Ramon Martin Chavez Márquez Independent Chairman
Benjamin Mabey Vice President-Software Engineering
Sector and Competitors
1st jan.Capi. (M$)
RECURSION PHARMACEUTICALS, INC.-31.93%2 018
GILEAD SCIENCES, INC.-11.95%80 128
REGENERON PHARMACEUTICALS, INC.11.70%75 415
VERTEX PHARMACEUTICALS33.16%74 991
BIONTECH SE-48.10%32 514
WUXI APPTEC CO., LTD.-38.82%28 423